Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

1.

Prediction of drug response in breast cancer using integrative experimental/computational modeling.

Frieboes HB, Edgerton ME, Fruehauf JP, Rose FR, Worrall LK, Gatenby RA, Ferrari M, Cristini V.

Cancer Res. 2009 May 15;69(10):4484-92. doi: 10.1158/0008-5472.CAN-08-3740. Epub 2009 Apr 14.

PMID:
19366802
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
[PubMed - indexed for MEDLINE]
3.

An integrated computational/experimental model of lymphoma growth.

Frieboes HB, Smith BR, Chuang YL, Ito K, Roettgers AM, Gambhir SS, Cristini V.

PLoS Comput Biol. 2013;9(3):e1003008. doi: 10.1371/journal.pcbi.1003008. Epub 2013 Mar 28.

PMID:
23555235
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Pharmacodynamic modeling of anti-cancer activity of tetraiodothyroacetic acid in a perfused cell culture system.

Lin HY, Landersdorfer CB, London D, Meng R, Lim CU, Lin C, Lin S, Tang HY, Brown D, Van Scoy B, Kulawy R, Queimado L, Drusano GL, Louie A, Davis FB, Mousa SA, Davis PJ.

PLoS Comput Biol. 2011 Feb 3;7(2):e1001073. doi: 10.1371/journal.pcbi.1001073.

PMID:
21304935
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Chemotherapy-resistant metastatic breast cancer.

Marquette C, Nabell L.

Curr Treat Options Oncol. 2012 Jun;13(2):263-75. doi: 10.1007/s11864-012-0184-6.

PMID:
22528367
[PubMed - indexed for MEDLINE]
6.
7.

Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors.

Liang Y, Besch-Williford C, Benakanakere I, Thorpe PE, Hyder SM.

Breast Cancer Res Treat. 2011 Jan;125(2):407-20. doi: 10.1007/s10549-010-0851-x. Epub 2010 Mar 27.

PMID:
20349129
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.

Kadra G, Finetti P, Toiron Y, Viens P, Birnbaum D, Borg JP, Bertucci F, Gonçalves A.

Breast Cancer Res Treat. 2012 Apr;132(3):1035-47. doi: 10.1007/s10549-011-1687-8. Epub 2011 Jul 27. Erratum in: Breast Cancer Res Treat. 2012 Jul;134(1):449-51.

PMID:
21792624
[PubMed - indexed for MEDLINE]
9.

Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.

Oliveras-Ferraros C, Vazquez-Martin A, López-Bonet E, Martín-Castillo B, Del Barco S, Brunet J, Menendez JA.

Int J Oncol. 2008 Dec;33(6):1165-76.

PMID:
19020749
[PubMed - indexed for MEDLINE]
10.

Mathematical modelling of tumour response in primary breast cancer.

Cameron DA, Gregory WM, Bowman A, Leonard RC.

Br J Cancer. 1996 Jun;73(11):1409-16.

PMID:
8645588
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Mechanistic modelling of dynamic MRI data predicts that tumour heterogeneity decreases therapeutic response.

Venkatasubramanian R, Arenas RB, Henson MA, Forbes NS.

Br J Cancer. 2010 Aug 10;103(4):486-97. doi: 10.1038/sj.bjc.6605773. Epub 2010 Jul 13.

PMID:
20628390
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment.

Pasquier E, Ciccolini J, Carre M, Giacometti S, Fanciullino R, Pouchy C, Montero MP, Serdjebi C, Kavallaris M, André N.

Oncotarget. 2011 Oct;2(10):797-809.

PMID:
22006582
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model.

Buchsbaum DJ, Zhou T, Grizzle WE, Oliver PG, Hammond CJ, Zhang S, Carpenter M, LoBuglio AF.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3731-41.

PMID:
14506165
[PubMed - indexed for MEDLINE]
Free Article
14.

A novel, patient-specific mathematical pathology approach for assessment of surgical volume: application to ductal carcinoma in situ of the breast.

Edgerton ME, Chuang YL, Macklin P, Yang W, Bearer EL, Cristini V.

Anal Cell Pathol (Amst). 2011;34(5):247-63. doi: 10.3233/ACP-2011-0019.

PMID:
21988888
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.

Wang X, Osada T, Wang Y, Yu L, Sakakura K, Katayama A, McCarthy JB, Brufsky A, Chivukula M, Khoury T, Hsu DS, Barry WT, Lyerly HK, Clay TM, Ferrone S.

J Natl Cancer Inst. 2010 Oct 6;102(19):1496-512. doi: 10.1093/jnci/djq343. Epub 2010 Sep 17.

PMID:
20852124
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy.

Olofsson MH, Ueno T, Pan Y, Xu R, Cai F, van der Kuip H, Muerdter TE, Sonnenberg M, Aulitzky WE, Schwarz S, Andersson E, Shoshan MC, Havelka AM, Toi M, Linder S.

Clin Cancer Res. 2007 Jun 1;13(11):3198-206.

PMID:
17545523
[PubMed - indexed for MEDLINE]
Free Article
17.

Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.

Rohwer N, Cramer T.

Drug Resist Updat. 2011 Jun;14(3):191-201. doi: 10.1016/j.drup.2011.03.001. Epub 2011 Apr 3. Review.

PMID:
21466972
[PubMed - indexed for MEDLINE]
18.

A new synthetic HDAC inhibitor, MHY218, induces apoptosis or autophagy-related cell death in tamoxifen-resistant MCF-7 breast cancer cells.

Park JH, Ahn MY, Kim TH, Yoon S, Kang KW, Lee J, Moon HR, Jung JH, Chung HY, Kim HS.

Invest New Drugs. 2012 Oct;30(5):1887-98. doi: 10.1007/s10637-011-9752-z. Epub 2011 Oct 8.

PMID:
21983700
[PubMed - indexed for MEDLINE]
19.

Consequences of cell-to-cell P-glycoprotein transfer on acquired multidrug resistance in breast cancer: a cell population dynamics model.

Pasquier J, Magal P, Boulangé-Lecomte C, Webb G, Le Foll F.

Biol Direct. 2011 Jan 26;6:5. doi: 10.1186/1745-6150-6-5.

PMID:
21269489
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Responsiveness to PI3K and MEK inhibitors in breast cancer. Use of a 3D culture system to study pathways related to hormone independence in mice.

Polo ML, Arnoni MV, Riggio M, Wargon V, Lanari C, Novaro V.

PLoS One. 2010 May 26;5(5):e10786. doi: 10.1371/journal.pone.0010786.

PMID:
20520761
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk